Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22109
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGow, Paul J-
dc.contributor.authorTestro, Adam G-
dc.contributor.authorHey, Penelope-
dc.contributor.authorSinclair, Marie-
dc.date2019-11-29-
dc.date.accessioned2019-12-02T05:16:56Z-
dc.date.available2019-12-02T05:16:56Z-
dc.date.issued2019-11-29-
dc.identifier.citationHepatology (Baltimore, Md.) 2019; online first: 29 November-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22109-
dc.description.abstractWe congratulate Dr Aberg and colleagues for a significant contribution to the literature on the important topic of moderate alcohol use in fatty liver disease (NAFLD) (1). Approximately 30% of the population of the Western world has obesity and/or other complications of insulin resistance and the metabolic syndrome. Due to the magnitude of this problem worldwide, palatable lifestyle therapies that are affordable, available and acceptable are necessary to curtail preventable early deaths. Moderate alcohol has the potential to fill this space, although knowledge remains limited.-
dc.language.isoeng-
dc.subjectNAFLD-
dc.subjectcardiovascular disease-
dc.subjectfibrosis-
dc.subjectmortality-
dc.subjectwine-
dc.titleModerate alcohol use in fatty liver disease; don't throw the cabernet out with the bathwater.-
dc.typeJournal Article-
dc.identifier.journaltitleHepatology (Baltimore, Md.)-
dc.identifier.affiliationVictorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationThe University of Melbourne, Victoria, Australia-
dc.identifier.doi10.1002/hep.31049-
dc.identifier.pubmedid31782819-
dc.type.austinLetter-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on May 8, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.